What is a Pharmacovigilance Inspection?

Introduction

Pharmacovigilance systems exist to protect patients and support the safe use of medicines.

Regulators expect Marketing Authorisation Holders to maintain systems capable of:

• Collecting safety information
• Evaluating safety concerns
• Reporting adverse reactions
• Monitoring benefit-risk balance
• Meeting regulatory obligations

However, regulators cannot directly observe these systems every day.

Instead, they periodically assess them through pharmacovigilance inspections.

Pharmacovigilance inspections are among the most important regulatory activities affecting pharmaceutical companies and pharmacovigilance organisations.

They provide regulators with an opportunity to evaluate whether a pharmacovigilance system is functioning effectively and whether patient safety obligations are being met.

What Is a Pharmacovigilance Inspection?

A pharmacovigilance inspection is a regulatory assessment conducted by a competent authority to determine whether a pharmacovigilance system complies with applicable legal and regulatory requirements.

Inspectors assess whether:

• Processes exist
• Processes are followed
• Responsibilities are understood
• Risks are managed appropriately
• Regulatory obligations are fulfilled

A useful definition is:

A pharmacovigilance inspection is a regulatory assessment designed to determine whether an organisation can demonstrate effective control of its pharmacovigilance system.

The emphasis is on demonstration.

Inspectors seek objective evidence rather than verbal assurances.

Why Do Pharmacovigilance Inspections Exist?

The primary purpose of pharmacovigilance regulation is patient protection.

Regulators therefore require confidence that organisations can:

• Detect safety issues
• Evaluate safety concerns
• Communicate risks
• Implement safety measures
• Comply with reporting obligations

Inspections help regulators verify these expectations.

Without inspections, regulators would have limited visibility regarding how pharmacovigilance systems function in practice.

What Are Inspectors Trying to Determine?

Although inspections review many documents and activities, inspectors are often trying to answer a small number of fundamental questions.

Does the Organisation Have an Effective Pharmacovigilance System?

Are Regulatory Requirements Being Met?

Are Risks Identified and Managed?

Is Oversight Effective?

Is Patient Safety Protected?

Most inspection activities ultimately relate to one or more of these questions.

Inspections Versus Audits

A common misconception is that audits and inspections are the same activity.

They are not.

Strong audit programmes often improve inspection readiness.

However, inspections remain independent regulatory activities.

For additional discussion see:

[[what-is-a-pharmacovigilance-audit]]

Types of Pharmacovigilance Inspections

Several inspection types may occur.

Routine Inspections

Performed as part of ongoing regulatory oversight.

For-Cause Inspections

Triggered by specific concerns.

Examples include:

• Safety concerns
• Compliance failures
• Regulatory signals

Triggered Inspections

Initiated following significant events.

Examples include:

• Organisational restructuring
• Major acquisitions
• Significant outsourcing activities

Pre-Authorisation Inspections

Conducted before certain regulatory decisions.

Post-Authorisation Inspections

Conducted after products enter the market.

These represent the most common inspection category.

The Inspection Lifecycle

Most inspections follow a broadly similar lifecycle.

Notification
      ↓
Preparation
      ↓
Inspection
      ↓
Findings
      ↓
CAPAs
      ↓
Follow-Up

Understanding this lifecycle helps organisations prepare effectively.

Inspection Notification

Inspections often begin with formal notification.

Authorities may request:

• PSMF
• Organisation charts
• Vendor lists
• SOPs
• Audit information
• Compliance metrics

Preparation activities usually begin immediately after notification.

Inspection Preparation

Effective preparation focuses on readiness rather than document production.

Areas commonly reviewed include:

• Documentation accuracy
• Governance arrangements
• Vendor oversight
• Audit history
• CAPA status
• QPPV visibility

The strongest organisations maintain readiness continuously rather than preparing only when inspections occur.

What Inspectors Review

Inspectors typically review multiple areas of the pharmacovigilance system.

Pharmacovigilance System Master File

System structure and governance.

QPPV Oversight

Leadership, accountability and visibility.

EudraVigilance Compliance

Reporting and data quality activities.

Vendor Oversight

Control of outsourced pharmacovigilance activities.

Safety Data Exchange Agreements

Allocation of responsibilities.

Audit Programmes

Independent assurance activities.

CAPA Programmes

Remediation effectiveness.

Governance Activities

Management oversight and escalation processes.

The exact scope depends upon inspection objectives.

The Importance of Evidence

Inspectors place significant emphasis on evidence.

Examples include:

• Records
• Reports
• Meeting minutes
• Metrics
• Audit results
• CAPA documentation

A documented process that cannot be demonstrated through evidence may be viewed as ineffective.

Interviews During Inspections

Inspectors frequently conduct interviews.

Common interviewees include:

• QPPVs
• Deputy QPPVs
• PV Managers
• Vendor Managers
• Quality Personnel

Interview objectives include:

• Confirming responsibilities
• Verifying understanding
• Assessing oversight effectiveness

Consistency between documentation and interviews is important.

Inspection Findings

Inspection findings identify deficiencies, weaknesses or compliance concerns.

Common classifications include:

Critical Findings

Highest regulatory significance.

Major Findings

Significant deficiencies requiring remediation.

Minor Findings

Lower-risk deficiencies.

Finding classification influences regulatory expectations and follow-up activities.

For additional discussion see:

[[inspection-findings]]

CAPAs Following Inspections

Inspection findings generally require CAPAs.

The objective is not simply correcting the issue.

The objective is preventing recurrence.

Regulators often evaluate:

• Root cause analysis
• CAPA quality
• Timeliness
• Effectiveness

Strong CAPAs frequently improve regulatory confidence.

The QPPV's Role

The QPPV plays a central role during many inspections.

Inspectors often expect the QPPV to demonstrate:

• Understanding of the pharmacovigilance system
• Awareness of significant risks
• Visibility regarding vendors
• Oversight of compliance activities

Inspectors are generally assessing oversight rather than operational execution.

Common Inspection Themes

Although inspection findings vary, recurring themes include:

Weak Governance

Poor Vendor Oversight

Inaccurate PSMFs

Limited QPPV Visibility

Weak CAPAs

Documentation-Reality Gaps

Understanding these themes helps organisations strengthen readiness.

Characteristics of Inspection-Ready Organisations

Inspection-ready organisations typically demonstrate:

Effective Governance

Accurate Documentation

Strong Oversight

Sustainable Compliance

Effective CAPAs

Continuous Improvement

Inspection readiness is usually the result of good pharmacovigilance management rather than short-term preparation.

Key Takeaways

• Pharmacovigilance inspections are regulatory assessments of pharmacovigilance systems.
• Inspectors seek evidence that organisations maintain effective control of their pharmacovigilance activities.
• Inspections differ fundamentally from audits.
• Inspectors review governance, compliance, oversight and risk management activities.
• Findings frequently relate to broader governance weaknesses.
• QPPVs play a central role during inspections.
• Effective CAPAs influence regulatory confidence significantly.
• Inspection readiness should be maintained continuously rather than created immediately before inspections.

References

1. EMA Good Pharmacovigilance Practices (GVP) Module III – Pharmacovigilance Inspections.
2. EMA Good Pharmacovigilance Practices (GVP) Module I – Pharmacovigilance Systems and Their Quality Systems.
3. EMA Good Pharmacovigilance Practices (GVP) Module II – Pharmacovigilance System Master File.
4. EMA Good Pharmacovigilance Practices (GVP) Module IV – Pharmacovigilance Audits.
5. Regulation (EC) No 726/2004.
6. Directive 2001/83/EC.
7. Commission Implementing Regulation (EU) No 520/2012.
8. ICH Q9 Quality Risk Management.
9. ICH Q10 Pharmaceutical Quality System.
10. PIC/S Guidance on Pharmacovigilance Inspections.